US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

FUNDX FUTURE FUND OPPORTUNITIES ETF

28.79

+0.36011.27%

Post-market: 28.800.0142+0.05%16:10 EDT

Volume:16.29K

Turnover:469.57K

Market Cap:234.46M

PE:- -

High:28.85

Open:28.73

Low:28.73

Close:28.43

52wk High:31.30

52wk Low:25.44

Shares:8.15M

Float Shares:8.15M

Volume Ratio:0.67

T/O Rate:0.20%

Dividend:0.49

Dividend Rate:1.72%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Halozyme announces proposed offering of $1.05B of 2033 convertible senior notes

Halozyme Plans USD 1.05 Billion Convertible Senior Notes Offering Due 2033

Halozyme Therapeutics, - Expects to Use Net Proceeds to Repurchase Outstanding 2027 and 2028 Convertible Notes

THOMSON REUTERS

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes Due 2033

THOMSON REUTERS

FireFox Gold Uncovers New High-Grade Lammas Zone at Mustajärvi Project in Finland

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live

Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS

Halozyme CEO Helen Torley Reports Disposal of Common Shares Worth USD 6.5 Million

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live

Rothschild & Co Redburn Initiates Guardant Health at Buy

MT Newswires Live

Guardant Health initiated with a Buy at Rothschild & Co Redburn

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer

THOMSON REUTERS

Analysts’ Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)

H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

Halozyme CEO, CFO to Speak at Wells Fargo Healthcare Conference Fireside Chat

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/FFOX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FFOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FFOX\",,,,,undefined,":{"symbol":"FFOX","market":"US","secType":"STK","nameCN":"FUNDX FUTURE FUND OPPORTUNITIES ETF","latestPrice":28.7858,"timestamp":1790971200000,"preClose":28.4257,"halted":0,"volume":16288,"hourTrading":{"tag":"盘后","latestPrice":28.8,"preClose":28.7858,"latestTime":"16:10 EDT","volume":7,"amount":201.5006,"timestamp":1790971805353,"change":0.0142,"changeRate":0.000493,"amplitude":0},"delay":0,"changeRate":0.01266811371399822,"floatShares":8145000,"shares":8145000,"eps":0,"marketStatus":"Market Closed","change":0.3601,"latestTime":"10-02 16:00:00 EDT","open":28.7338,"high":28.8499,"low":28.7338,"amount":469571,"amplitude":0.004084,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":28.4257,"sharesOutstanding":7155000,"nav":28.42,"aum":231480900,"dividendRate":0.017168,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.8,"preClose":28.7858,"latestTime":"16:10 EDT","volume":7,"amount":201.5006,"timestamp":1790971805353,"change":0.0142,"changeRate":0.000493,"amplitude":0},"volumeRatio":0.665272512310037},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FFOX\",,,,,undefined,":{"symbol":"FFOX","floatShares":8145000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.665272512310037,"shares":8145000,"dividePrice":0.4942,"high":28.8499,"amplitude":0.004084,"preClose":28.4257,"low":28.7338,"week52Low":25.44,"pbRate":"--","week52High":31.295,"institutionHeld":0,"latestPrice":28.7858,"eps":0,"divideRate":0.017168,"volume":16288,"delay":0,"ttmEps":0,"open":28.7338,"prevYearClose":27.27,"prevWeekClose":28.495,"prevMonthClose":28.24,"prevQuarterClose":28.24,"fiveDayClose":28.495,"twentyDayClose":29.1269,"sixtyDayClose":29.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FFOX\",params:#limit:5,,,undefined,":[{"date":"2025-12-31","symbol":"FFOX","amount":0.49447507,"announcedDate":"2025-12-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-31","defaultRemindTime":1767191400000,"name":"FUNDX FUTURE FUND OPPORTUNITIES ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-02","payableDate":"2025-12-31","currency":"USD","dateTimestamp":1767157200000,"payDate":"2026-01-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FFOX\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-31","recordDate":"2025-12-31","paymentDate":"2026-01-02","value":0.49447507,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FFOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FFOX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668985935","title":"Halozyme announces proposed offering of $1.05B of 2033 convertible senior notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2668985935","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668985935?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:35","pubTimestamp":1789590922,"startTime":"0","endTime":"0","summary":"Halozyme (HALO) Therapeutics “announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/halozyme-announces-proposed-offering-of-1-05b-of-2033-convertible-senior-notes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/halozyme-announces-proposed-offering-of-1-05b-of-2033-convertible-senior-notes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FFOX","BK4139","HALO","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668895935","title":"Halozyme Plans USD 1.05 Billion Convertible Senior Notes Offering Due 2033","url":"https://stock-news.laohu8.com/highlight/detail?id=2668895935","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668895935?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:31","pubTimestamp":1789590696,"startTime":"0","endTime":"0","summary":"Halozyme plans USD 1.05 billion convertible senior notes offering due 2033Halozyme announced a proposed offering of USD 1.05 billion convertible senior notes due 2033.Deal includes a 13-day option for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL8s1KsF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","BK4139","FFOX","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668933044","title":"Halozyme Therapeutics, - Expects to Use Net Proceeds to Repurchase Outstanding 2027 and 2028 Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2668933044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668933044?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:30","pubTimestamp":1789590601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA8FSWC6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HALO","FFOX","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668330229","title":"Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes Due 2033","url":"https://stock-news.laohu8.com/highlight/detail?id=2668330229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668330229?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:30","pubTimestamp":1789590601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA8FSWC6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HALO","FFOX","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667898849","title":"FireFox Gold Uncovers New High-Grade Lammas Zone at Mustajärvi Project in Finland","url":"https://stock-news.laohu8.com/highlight/detail?id=2667898849","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667898849?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:56","pubTimestamp":1789559762,"startTime":"0","endTime":"0","summary":"An update from FireFox Gold ( ($TSE:FFOX) ) is now available. FireFox Gold has announced the discovery of the Lammas Zone, a newly recognized high-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/firefox-gold-uncovers-new-high-grade-lammas-zone-at-mustajarvi-project-in-finland?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/firefox-gold-uncovers-new-high-grade-lammas-zone-at-mustajarvi-project-in-finland?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGUmain","GCmain","FFOX","GLD","GDX","NUGT","159934","SGCmain","DUST","IAU","MGCmain","518880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667062145","title":"Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667062145","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667062145?lang=en_us&edition=fundamental","pubTime":"2026-09-16 03:02","pubTimestamp":1789498945,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the result preserves the biomarker-driven monitoring approach supporting potential demand for its Guardant","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443895.HKD","LU0889565916.HKD","BK4196","LU0708994859.HKD","BK4588","LU2462157665.USD","BK4568","LU2237443549.SGD","LU2237443978.SGD","LU0310800379.SGD","PTH","GH","LU2237443382.USD","LU2237443465.HKD","AZNH","LU1829250122.USD","GDOC","HELX","LU0029864427.USD","LU2237443622.USD","LU0128525929.USD","LU2236285917.USD","LU1267930573.SGD","BK4007","LU2089984988.USD","LU0058720904.USD","LU2456880835.USD","GNMX","FFOX","BK4535","AZN","LU0320765992.SGD","LFSC","BK4551","LU2468319806.SGD","IE00B3T34201.USD","GNOM","LU0289739699.SGD","BK4585","LU0109394709.USD","LU2417539215.USD","EKG","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667569983","title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2667569983","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667569983?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:12","pubTimestamp":1789423938,"startTime":"0","endTime":"0","summary":"Guardant Health CIO Kumud Kalia disposes of 4,000 common shares worth $632,193.20Guardant Health Chief Information Officer Kumud Kalia sold 4,000 common shares on Sept. 11, 2026.The sale price was USD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL3DVtS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4196","GDOC","HELX","BK4588","GNMX","LU0109394709.USD","FFOX","LFSC","PTH","GH","BK4585","LU0889565916.HKD","LU0320765992.SGD","GNOM","EKG","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667087693","title":"Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667087693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667087693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:07","pubTimestamp":1789416443,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN4560HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4196","LU0889565916.HKD","FFOX","LU0320765992.SGD","LFSC","BK4551","PTH","BK4585","GDOC","GH","EKG","HELX","GNMX","BK4535","LU0109394709.USD","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666570911","title":"Halozyme CEO Helen Torley Reports Disposal of Common Shares Worth USD 6.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666570911","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666570911?lang=en_us&edition=fundamental","pubTime":"2026-09-12 08:35","pubTimestamp":1789173359,"startTime":"0","endTime":"0","summary":"Halozyme CEO Helen Torley reports disposal of common shares worth USD 6.5 millionHalozyme CEO Helen Torley reported option exercises totaling 60,000 shares from Sept. 9-11, 2026 at USD 18.41.Disposed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260912:nNDL9QbYMF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Halozyme CEO Helen Torley Reports Disposal of Common Shares Worth USD 6.5 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","BK4139","LU0053671581.USD","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666368655","title":"UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666368655","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666368655?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:35","pubTimestamp":1788960920,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","BK4588","BK4535","PTH","GDOC","LU0109394709.USD","BK4585","GNMX","BK4551","GNOM","GH","HELX","FFOX","LFSC","LU0889565916.HKD","EKG","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373511","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373511?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871865,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN), Guardant Health (GH) and Neurocrine (N...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","LU0058720904.USD","LU2065170008.USD","LU2468319806.SGD","BK4533","IBBQ","IE0009355771.USD","BK4534","BIB","IE00BJT1NW94.SGD","LU2242646821.SGD","XBI","XLV","LU1057294990.SGD","HCSG","AMGN","BK4585","NBIX","LU0029874061.USD","GH","HELX","LU0154245756.USD","IE0002141913.USD","GNMX","PJP","LU1061106388.HKD","GDOC","LU0289739699.SGD","BBH","IE00B2B36J28.USD","LFSC","TBXU","FFOX","LU0154245673.USD","IBB","LU0109394709.USD","LABU","LU0889565916.HKD","PTH","BK4535","BK4139","LU0823416689.USD","EKG","BK4588","BK4137","LU1571399168.USD","LU2242652126.USD","PBE","GNOM","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378332","title":"Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378332?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:26","pubTimestamp":1788870360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4196","LFSC","BK4585","GH","LU0889565916.HKD","LU0109394709.USD","HELX","GDOC","FFOX","BK4551","GNOM","GNMX","LU0320765992.SGD","BK4588","EKG","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321994","title":"Guardant Health's Breast Cancer Diagnostic Approved by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321994","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321994?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:08","pubTimestamp":1788862114,"startTime":"0","endTime":"0","summary":"Guardant Health's  Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's  Etcamah, the company said.The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.Shares of the company were up 1% in recent premarket trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0310800379.SGD","BK4551","LU0058720904.USD","LU2456880835.USD","LU2468319806.SGD","LU2089984988.USD","LU2237443895.HKD","LU0432979614.USD","LU1829250122.USD","LU2462157665.USD","BK4585","LU0029864427.USD","BK4007","LU2237443978.SGD","GH","HELX","AZN","GNMX","AZNH","GDOC","LU2237443622.USD","LU0289739699.SGD","LFSC","BK4196","FFOX","LU2237443465.HKD","PTH","LU0109394709.USD","LABU","IE00B3T34201.USD","LU0889565916.HKD","LU0708994859.HKD","LU0128525929.USD","BK4535","LU2417539215.USD","LU2236285917.USD","LU2237443382.USD","EKG","BK4588","LU1267930573.SGD","BK4568","GNOM","LU0320765992.SGD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665213403","title":"Rothschild & Co Redburn Initiates Guardant Health at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665213403","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665213403?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:01","pubTimestamp":1788861705,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LFSC","PTH","BK4551","BK4535","BK4585","GNOM","HELX","LU0320765992.SGD","FFOX","GDOC","BK4588","LU0109394709.USD","EKG","GNMX","BK4196","GH","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532615","title":"Guardant Health initiated with a Buy at Rothschild & Co Redburn","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532615?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:16","pubTimestamp":1788858969,"startTime":"0","endTime":"0","summary":"Rothschild & Co Redburn initiated coverage of Guardant Health (GH) with a Buy rating and $203 price target The firm says Guardant is the leader in ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","GH","FFOX","LU0320765992.SGD","GNOM","HELX","BK4551","EKG","GNMX","LFSC","PTH","BK4588","BK4585","GDOC","LU0109394709.USD","BK4535","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354019","title":"Guardant announces FDA approval of Guardant360 CDx as companion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354019","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354019?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:15","pubTimestamp":1788560112,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patien...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEIH","LU0889565916.HKD","LFSC","LU0320765992.SGD","BBP","SYNB","TECB","EKG","PINK","BMED","BK4551","BK4585","IBB","BK4535","GH","PSCH","XLVX","PTH","BK4588","IDNA","LU0109394709.USD","MEDI","GDOC","IYH","NVIB","GNMX","FRTY","FFOX","MRNX","HELX","LABU","TBXU","MRNY","RSPH","GNOM","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354794","title":"Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354794?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:10","pubTimestamp":1788559800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA7GZLSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","LU0889565916.HKD","LU0109394709.USD","GNOM","GNMX","EKG","BK4551","LFSC","BK4535","FFOX","GH","HELX","BK4588","PTH","LU0320765992.SGD","GDOC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664846503","title":"Analysts’ Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664846503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664846503?lang=en_us&edition=fundamental","pubTime":"2026-09-03 02:50","pubTimestamp":1788375009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on High Roller Technologies, Inc. (ROLR) and Halozyme (HALO) wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-high-roller-technologies-inc-rolr-halozyme-halo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-high-roller-technologies-inc-rolr-halozyme-halo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HRLR","NA","BK4141","HALO","ROLR","FFOX","LU0053671581.USD","BK4150","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664843956","title":"H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme","url":"https://stock-news.laohu8.com/highlight/detail?id=2664843956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664843956?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:40","pubTimestamp":1788367217,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reiterates a Buy rating on Halozyme (HALO) with a $115 price target after Novartis (NVS) signed an option and license agreement wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-views-novartis-alteogen-pact-as-negative-for-halozyme-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-views-novartis-alteogen-pact-as-negative-for-halozyme-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","PPH","BK4585","BK4588","NVS","IE00B2B36J28.USD","LU0211331839.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","MEDX","BK4139","BK4007","LU0070302665.USD","IE00BFTCPJ56.SGD","FFOX","LU0053671581.USD","IE00B4R5TH58.HKD","LU0320765489.SGD","HALO","BK4532","IE00BJT1NW94.SGD","BK4578","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811474","title":"Halozyme CEO, CFO to Speak at Wells Fargo Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811474","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811474?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:32","pubTimestamp":1788352367,"startTime":"0","endTime":"0","summary":"Halozyme CEO, CFO to speak at Wells Fargo healthcare conference fireside chatHalozyme will join Wells Fargo’s 21st Annual Healthcare Conference on Sept. 9, 2026, featuring a fireside chat.Management w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL136P6d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","HALO","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":109,"code":"91000000","status":"200"}]}}